Human γδ T cells have displayed their potential in cancer immunity through efficient tumor killing activities. Besides, they are also known for their capacity of antigen presentation. How to improve γδ T cells' immunotherapeutic effect as the cell vaccine is still a great challenge. Herein, we explore the human γδ T cells and tumor cell fused vaccine for enhanced immunotherapeutic efficacy of osteosarcoma. The fusion cell vaccine was prepared by chemical fusion between human γδ T cells and inactive osteosarcoma Saos-2 cells. The fusion process was confirmed by microscopy observation, and flow cytometry analysis further validated the antigen presenting functions of the fusion cells. Moreover, the immunotherapeutic potential of the fusion cells was then verified via cytotoxicity assay and cytokine release detection. Our study provided novel immunotherapeutic strategy for patients with osteosarcoma, which merits further practice in the near future.

人类γδT细胞通过有效的肿瘤杀伤活性显示了其在癌症免疫中的潜力。此外，它们还以其抗原呈递能力而闻名。作为细胞疫苗，如何提高γδT细胞的免疫治疗效果仍然是一个巨大的挑战。在这里，我们探索人γδT细胞和肿瘤细胞融合疫苗，以增强骨肉瘤的免疫治疗效果。融合细胞疫苗是通过人γδT细胞和无活性骨肉瘤Saos-2细胞之间的化学融合制备的。通过显微镜观察证实了融合过程，并且流式细胞术分析进一步证实了融合细胞的抗原呈递功能。此外，融合细胞的免疫治疗潜力随后通过细胞毒性测定和细胞因子释放检测。我们的研究为骨肉瘤患者提供了新颖的免疫治疗策略，值得在不久的将来进一步实践。